25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,451 shares of the biopharmaceutical company’s stock, valued at approximately $11,389,000.

A number of other hedge funds also recently modified their holdings of ALNY. Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $25,000. Salomon & Ludwin LLC bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $27,000. ORG Partners LLC raised its stake in shares of Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares in the last quarter. Quent Capital LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $39,000. Finally, Hilltop National Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $41,000. Institutional investors own 92.97% of the company’s stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Barclays initiated coverage with an overweight (positive) recommendation — new institutional attention and an overweight start can attract buyers and support the share price. Barclays Initiates Coverage on Alnylam
• Positive Sentiment: Bank of America lowered its price target from $529 to $462 but maintained a Buy rating (implies ~36.7% upside vs. current price), which is supportive versus a full downgrade. BofA PT cut to $462
• Positive Sentiment: HC Wainwright cut its target from $570 to $510 but kept a Buy rating (implies ~50.9% upside), another vote of confidence from a sell-side firm. HC Wainwright PT cut to $510
• Positive Sentiment: Alnylam outlined a new five?year strategy, “Alnylam 2030,” and is projecting ~ $5.3B revenue for 2026 — strategic growth targets and a multi?year plan can support investor confidence in long?term upside. Alnylam projects 2026 revenue ~$5.3B
• Neutral Sentiment: Alnylam will webcast a conference call to discuss Q4 and full?year 2025 results — standard corporate event that may move the stock depending on actual results and guidance. Webcast of Q4/FY2025 results
• Neutral Sentiment: Reported short?interest data shows effectively zero reported short position (data appears inconsistent/placeholder); this item is unlikely to explain intraday moves. (Internal short?interest report)
• Negative Sentiment: Morgan Stanley lowered its price target from $495 to $408 and moved to an Equal Weight rating — a visible downgrade in sentiment from a major bank which likely pressured the stock. Morgan Stanley PT cut to $408
• Negative Sentiment: Technical context: the stock is trading below both its 50?day (~$401.57) and 200?day (~$423.47) moving averages, which can amplify downside as trend?following and momentum flows react.

Analyst Ratings Changes

Several research analysts recently issued reports on ALNY shares. Wells Fargo & Company dropped their price target on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Bank of America cut their price objective on Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating for the company in a report on Friday. Finally, Raymond James Financial restated an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $477.13.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 56,955 shares of company stock worth $24,072,733. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ ALNY opened at $338.06 on Monday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The firm’s 50-day simple moving average is $399.61 and its 200 day simple moving average is $425.13. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The company has a market cap of $44.66 billion, a price-to-earnings ratio of 1,408.58 and a beta of 0.35.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.